Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of inflammatory response in hepatorenal syndrome, Relationship with kidney outcome and survival

  • Solé Martí, Cristina|||0000-0002-6104-8345
  • Solà, Elsa|||0000-0001-6897-2760
  • Huelin, Patricia
  • Carol, Marta
  • Moreira, Rebeca
  • Cereijo, Unai|||0000-0003-1557-8836
  • Mas, José-Manuel
  • Graupera, Isabel|||0000-0001-9170-9784
  • Pose, Elisa|||0000-0002-0224-7686
  • Napoleone, Laura
  • dePrada, Gloria
  • Juanola, Adrià|||0000-0003-4832-5130
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Torres, Ferran|||0000-0002-7355-7913
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Farrés, Judith
  • Jiménez, Wladimiro|||0000-0002-9376-0214
  • Ginès, Pere|||0000-0003-4657-4504
Several lines of evidence indicate that decompensated cirrhosis is characterized by the presence of systemic inflammation. Hepatorenal syndrome (HRS-AKI) is a unique type of renal failure that occurs at late stages of cirrhosis. However, confirmation of the presence and significance of such inflammatory response in HRS-AKI is lacking. To characterize the systemic inflammatory response, as estimated by measuring a large number of cytokines, in 161 patients hospitalized for an acute decompensation of cirrhosis: 44 patients without acute kidney injury (AKI), 63 patients with hypovolaemia-induced AKI and 58 patients with HRS-AKI. HRS-AKI was characterized by an altered cytokine profile compared to the other two groups, particularly IL-6, IL-8, TNF-α, VCAM-1, fractalkine and MIP-1α. The inflammatory response was not related to presence of bacterial infection, concomitant acute-on-chronic liver failure or severity of renal dysfunction. Patients who responded to terlipressin and albumin had only a decrease in TNF-α and RANTES after treatment without changes in other cytokines. Interestingly, patients with persistent HRS-AKI had higher levels of IP-10 and VCAM-1 compared to those with resolution of HRS-AKI. VCAM-1 was also an independent predictor of 3-month mortality. A systems biology analysis approach showed that the inflammatory status of HRS-AKI was similar to that of chronic nonhepatic inflammatory conditions, such as lupus erythematosus or inflammatory bowel disease. Hepatorenal syndrome is characterized by a marked systemic inflammatory state, reminiscent of that of nonhepatic inflammatory diseases, that correlates with patient outcomes. See Editorial on Page.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Adipocyte fatty-acid binding protein is overexpressed in cirrhosis and correlates with clinical outcomes

  • Graupera, Isabel|||0000-0001-9170-9784
  • Coll, Mar|||0000-0003-3726-0087
  • Pose, Elisa|||0000-0002-0224-7686
  • Elia, Chiara
  • Piano, Salvatore|||0000-0002-9356-5830
  • Solà, Elsa|||0000-0001-6897-2760
  • Blaya, Delia
  • Huelin, Patricia
  • Solé Martí, Cristina|||0000-0002-6104-8345
  • Moreira, Rebeca
  • De Prada, Gloria
  • Fabrellas, Núria|||0000-0001-6720-0291
  • Juanola, Adrià|||0000-0003-4832-5130
  • Morales Ruiz, Manuel|||0000-0002-9074-2272
  • Sancho-Bru, Pau|||0000-0001-5569-9259
  • Villanueva, Càndid|||0000-0002-3674-914X
  • Ginès, Pere|||0000-0003-4657-4504
Fatty-acid-binding proteins (FABPs) are small intracellular proteins that coordinate lipid-mediated processes by targeting metabolic and immune response pathways. The aim of the study was to investigate plasma FABPs levels and their relationship with clinical outcomes in cirrhosis. Plasma levels of L-FABP1(liver and kidney), I-FABP2(intestine), and A-FABP4(adipocyte and macrophages) were measured in 274 patients with decompensated cirrhosis. Hepatic gene expression of FABPs was assessed in liver biopsies from patients with decompensated cirrhosis and in liver cell types from mice with cirrhosis. Immunohistochemistry of A-FABP4 in human liver biopsy was also performed. Plasma levels of FABPs were increased in patients with decompensated cirrhosis compared to those of healthy subjects (L-FABP1: 25 (17-39) vs 10 (9-17) ng/mL p = 0.001, I-FABP2: 1.1 (0.5-2.1) vs 0.6 (0.4-1) ng/mL p = 0.04 and A-FABP4: 37 (20-68) vs 16 (11-33) ng/mL p = 0.002), respectively. Increased A-FABP4 levels were associated with complications of cirrhosis, acute-on-chronic liver failure and poor survival. Hepatic A-FABP4 gene expression was upregulated in decompensated cirrhosis. Macrophages were the main liver cell that over-expressed A-FABP4 in experimental cirrhosis and increased A-FABP4 was found in macrophages of human biopsies by immunohistochemistry. A-FABP4 levels are increased in decompensated cirrhosis and correlate with poor outcomes. Liver macrophages appear to be the main source of A-FABP4 in decompensated cirrhosis.